Loading...
Skin and soft-tissue infections (SSIs) are common and affect patients of all ages. Many such infections are caused by methicillin-resistant Staphylococcus aureus, for which current therapies are limited. Now, researchers have published the results of manufacturer-sponsored clinical trials comparing the lipoglycopeptides dalbavancin and oritavancin with “standard therapy” in adults with acute bacterial SSIs. Dalbavancin has just received FDA approval (NEJM JW Infect Dis Jun 3 2014); a ruling on oritavancin is expected soon.
In two multicenter, multinational, double-blind, double-dummy, randomized trials, Boucher and colleagues compared dalbavancin (1 dose intravenously on days 1 and 8) with vancomycin (1 dose intravenously every 12 hours, wit…